← Back to feed

Fusion Antibodies

FAB · AIM · Health Care · mcap £14m today

All announcements

All RNS · 35 Key events · 20

05 Oct 26

Launch of new customer-focused website

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces the launch of its new customer-focused website.
RNS 9805360 ↗
22 Sep 26

Posting of Annual Report & Notice of AGM
RNS 9783262 ↗
15 Sep 26

Final Results

The following amendment has been made to the announcement released on 14 September 2026 at 7am under RNS No.
RNS 9773630 ↗
14 Sep 26

Final Results

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its final results for the year ended 31 March 2026.
RNS 9769010 ↗
09 Sep 26

Grant of Canadian Patent for OptiMAL

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Company's patent application no.
RNS 9763615 ↗
09 Sep 26

Notice of Results
RNS 9761961 ↗
06 Aug 26

Notice of acceptance of patent in Australia

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that IP Australia has issued a notice of acceptance in respect of the Company's...
RNS 9707342 ↗
20 Jul 26

Grant of options
RNS 9676935 ↗
01 Jul 26

Holding(s) in Company
RNS 9648188 ↗
30 Jun 26

Total Voting Rights
RNS 9645361 ↗
22 Jun 26

Notice of allowance of patent in Canada

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that the Canadian Intellectual Property Office has issued a notice of allowance in...
RNS 9628760 ↗
15 Jun 26

Update on grant-funded DR5 project

Project to develop a DR5 humanised therapeutic antibody to combat treatment-resistant cancers
RNS 9617242 ↗
02 Jun 26

Exercise of options and total voting rights
RNS 9595962 ↗
11 May 26

Holding(s) in Company
RNS 9562368 ↗
11 May 26

Grant of patent in Japan

Grant strengthens antibody discovery platform and licensing opportunities
RNS 9561846 ↗
05 May 26

Year-end trading statement

Positioning for growth through platform development and strategic partnerships
RNS 9550653 ↗
30 Mar 26

Antibody IP transfer agreement

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that it has entered into an agreement to transfer the ownership of certain background...
RNS 9496984 ↗
17 Feb 26

Director/PDMR Shareholding
RNS 9434609 ↗
04 Feb 26

Holding(s) in Company
RNS 9408973 ↗
02 Feb 26

Holding(s) in Company
RNS 9401678 ↗
30 Jan 26

Total Voting Rights
RNS 9397032 ↗
27 Jan 26

Issue of Director Shares

As disclosed in the Company's annual report and accounts for the year ended 31 March 2025 (as announced on 4 September 2025), the remuneration committee recommended, and the board of directors of Fusion (the "Board" or the "Directors") accepted, a bonus...
RNS 9388207 ↗
27 Jan 26

Placing and Subscription to raise approx £1.4m

Placing and Subscription to raise approximately £1.4 million
RNS 9388010 ↗
19 Dec 25

Update on negotiations with NCI regarding OptiMAL

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that following the validation project run with the National Cancer Institute ("NCI")...
RNS 9307856 ↗
16 Dec 25

Launch of OptiMAL platform

Launch of the OptiMAL® Human Antibody Discovery platform
RNS 9300118 ↗
11 Dec 25

Mammalian Display video

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that ahead of the commercial launch of the OptiMAL® Human Antibody Discovery platform...
RNS 9289286 ↗
25 Nov 25

Holding(s) in Company
RNS 9256115 ↗
24 Nov 25

Half-year Results

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces its unaudited interim results for the six months ended 30 September 2025 ("H1 FY2026").
RNS 9251785 ↗
21 Nov 25

Notice of Results
RNS 9248269 ↗
13 Nov 25

OptiMAL Library video

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, has prepared a short video of Dr Richard Buick, CSO, explaining some of the features, science...
RNS 9230310 ↗
03 Nov 25

OptiMAL® R&D Update

Validation of OptiMAL® for the isolation of specific antibodies against proteins and peptides
RNS 9207403 ↗
27 Oct 25

Holding(s) in Company
RNS 9197091 ↗
16 Oct 25

Result of AGM
RNS 9175802 ↗
16 Oct 25

AGM statement and H1 trading update

Fusion Antibodies plc (AIM: FAB), specialists in pre-clinical antibody discovery, engineering and supply for both therapeutic drug and diagnostic applications, announces that at the Company's AGM, being held later today, Simon Douglas, Chairman, will...
RNS 9173988 ↗
08 Oct 25

Contract win

New multi-target Humanisation project with global pharmaceutical company
RNS 9156794 ↗

Source: Investegate RNS archive. Quotes are short extracts. Not investment advice.